Medicortex USA Ltd. attending the 2nd TBI-Challenge.eu 2013
Medicortex USA Ltd. announced today that the company has been invited to attend the 2nd TBI-Challenge.eu 2013 BIENNIAL INTERDISCIPLINARY CONFERENCE of the BRAIN INJURY AND FAMILIES / EUROPEAN FEDERATION (BIF) on September 19-21, 2013 at the University of Vienna, Austria.
[ClickPress, Sat Aug 31 2013] Medicortex USA Ltd. announced today that the company has been invited to attend the 2nd TBI-Challenge.eu 2013 BIENNIAL INTERDISCIPLINARY CONFERENCE of the BRAIN INJURY AND FAMILIES / EUROPEAN FEDERATION (BIF) on September 19-21, 2013 at the University of Vienna, Austria.
“Traumatic Brain Injury (TBI) is the second frequent neurological disease, directly after the ischemic stroke. It represents a silent burden all over the world and is constantly growing. TBI is difficult to diagnose because of the many different performances in each individual after the trauma. It doesn’t only concern the injured patient itself but also the surrounding family, the social environment, as well as health facilities and social security professionals. Up to date, there is no drug that could address specifically the development of the primary and second injury to the brain upon TBI”.
Dr. Adrian Harel, Medicortex’s owner and CEO, stated: “We are proud to attend and to present the potential of our under development drugs aimed to mitigate the harmful effects of TBI. The company has designed three chemically verified proprietary, each with lipophilic properties for crossing the brain-blood-barrier (BBB), as well as at least two neuroprotective functions, e.g. free metal ion binding, anti-oxidation, anti-inflammation, and/or anti-bacterial. Medicortex will present its plan for initial studies for assessing the biological activity and lack of toxicity of its pipeline compounds.”
According to the National Centers for Disease Control (CDC), there are approximately one million TBI incidences in the US each year. Of these, an estimated 5% - 15% suffer from moderate to severe permanent brain impairment. Secondary brain injury in patients with severe or mild TBI occurs as a result of increased permeability of the neuronal membrane, followed by an excessive influx of metal ions and circulating free radicals. This causes a series of protein degradation cascades and oxidation, leading to widespread molecular damage and neuronal cell death. The outcomes of this chain of events include persistent disability and even death.
Medicortex, is currently in the proof-of-concept stage dedicated to drug discovery for acute neurodegenerative conditions, such as TBI, stroke, toxic nerve agent exposure, and other neurodegenerative conditions. The company's initial focus is on preventing secondary brain injury in TBI, a complex process caused by a multitude of biochemical changes. Medicortex's unique neuroprotective strategy is to introduce a multi-functional compound that will address a number of biochemical & physiological pathways simultaneously. Medicortex is a privately held company founded in 2010 by Dr. Adrian Harel, an experienced neurobiologist with a track record in business management and leadership of early-stage drug discovery companies. His collaboration with renowned experts in medicinal chemistry promises to generate a successful pipeline of innovative molecules for the treatment of acute neurodegenerative disorders such as TBI.
Contact: Dr. Adrian Harel, CEO